
## Helena Tavares De Sousa

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/12023477/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Subclinical Persistent Inflammation as Risk Factor for Crohn's Disease Progression: Findings From a Prospective Real-World Study of 2 Years. Clinical Gastroenterology and Hepatology, 2022, 20, 2059-2073.e7.	4.4	4
2	Histologic Features of Colon Biopsies (Geboes Score) Associated With Progression of Ulcerative Colitis for the First 36 Months After Biopsy. Clinical Gastroenterology and Hepatology, 2021, 19, 2567-2576.e9.	4.4	12
3	lleal Crohn's Disease Exhibits Similar Transmural Fibrosis Irrespective of Phenotype. Clinical and Translational Gastroenterology, 2021, 12, e00330.	2.5	8
4	Comparing the Continuous Geboes Score With the Robarts Histopathology Index: Definitions of Histological Remission and Response and their Relation to Faecal Calprotectin Levels. Journal of Crohn's and Colitis, 2020, 14, 169-175.	1.3	25
5	The new simplified MARIA score applies beyond clinical trials: A suitable clinical practice tool for Crohn's disease that parallels a simple endoscopic index and fecal calprotectin. United European Gastroenterology Journal, 2020, 8, 1208-1216.	3.8	21
6	Comparison of the Nancy Index With Continuous Geboes Score: Histological Remission and Response in Ulcerative Colitis. Journal of Crohn's and Colitis, 2020, 14, 1021-1025.	1.3	18
7	Transmural Histological Scoring Systems in Crohn's Disease: A Systematic Review With Assessment of Methodological Quality and Operating Properties. Journal of Crohn's and Colitis, 2020, 14, 743-756.	1.3	5
8	Soluble human Suppression of Tumorigenicity 2 is associated with endoscopic activity in patients with moderate-to-severe ulcerative colitis treated with golimumab. Therapeutic Advances in Gastroenterology, 2019, 12, 175628481986914.	3.2	4
9	Comparison of different histological indexes in the assessment of UC activity and their accuracy regarding endoscopic outcomes and faecal calprotectin levels. Gut, 2019, 68, 594-603.	12.1	83
10	New cross-sectional imaging in IBD. Current Opinion in Gastroenterology, 2018, 34, 194-207.	2.3	18
11	Accuracy of Faecal Calprotectin and Neutrophil Gelatinase B-associated Lipocalin in Evaluating Subclinical Inflammation in UlceRaTIVE Colitis—the ACERTIVE study. Journal of Crohn's and Colitis, 2017, 11, jjw170.	1.3	22
12	Calprotectin and the Magnitude of Antibodies to Infliximab in Clinically-stable Ulcerative Colitis Patients are More Relevant Than Infliximab Trough Levels and Pharmacokinetics for Therapeutic Escalation. EBioMedicine, 2017, 21, 123-130.	6.1	8
13	Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 2: Current Management. Journal of Crohn's and Colitis, 2017, 11, 769-784.	1.3	876
14	Therapeutic drug monitoring of CT-P13: a comparison of four different immunoassays. Therapeutic Advances in Gastroenterology, 2017, 10, 661-671.	3.2	16
15	Clinical performance of an infliximab rapid quantification assay. Therapeutic Advances in Gastroenterology, 2017, 10, 651-660.	3.2	16
16	Detection of anti-infliximab antibodies is impacted by antibody titer, infliximab level and IgG4 antibodies: a systematic comparison of three different assays. Therapeutic Advances in Gastroenterology, 2016, 9, 781-794.	3.2	15